Deal Announcements

Immunotope Nets Second Funding From Ben Franklin

Wednesday, June 27, 2007 5:00:00 AM PDT | VentureDeal Staff

DOYLESTOWN, PA -- Vaccine developer Immunotope, Inc. announced that it has received a second progress funding, in the amount of $350,000.

Immunotope is developing a ovarian and breast cancer vaccine and is in Phase I clinical trial.  The vaccine candidate, IMT-1012, is being targeted at patients who have advanced-stage cancer and for whom there are no further treatment options.

The investor was Ben Franklin Technology Partners of Southeastern PA.  BFTP was formed in 1982 and has funded more than 1,600 regional enterprises with more than $130 million since its inception.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1